Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
174,953,530
-
Shares change
-
+3,379,818
-
Total reported value, excl. options
-
$4,431,556,073
-
Value change
-
+$57,307,408
-
Put/Call ratio
-
32%
-
Number of buys
-
147
-
Number of sells
-
106
-
Price
-
$25.33
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q2 2024
As of 30 Jun 2024 BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) had 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 174,953,530 shares of stock of the company.
Largest 10 holders included Kohlberg Kravis Roberts & Co. L.P., VIKING GLOBAL INVESTORS LP, VANGUARD GROUP INC, BlackRock Inc., Aisling Capital Management LP, STATE STREET CORP, Laurion Capital Management LP, JANUS HENDERSON GROUP PLC, Frazier Life Sciences Management, L.P., and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 249 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.